• The Clorox Company recently reported its third-quarter fiscal 2026 results, showing slightly higher earnings but a small revenue decline amid ongoing cost pressures and softer demand.
• Management continues to lean on its IGNITE strategy and cost-saving programs to help offset margin pressure and steady performance in a volatile operating backdrop.
• We’ll now examine how elevated cost pressures highlighted in the latest quarter may influence Clorox’s broader investment narrative and outlook.

AI is about to change healthcare. These 34 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Clorox Investment Narrative Recap

To own Clorox, you need to believe its core brands, cost controls, and IGNITE strategy can offset sluggish categories and competitive pressure. The latest quarter’s slightly higher earnings but softer revenue do not appear to change the near term story much: the key catalyst remains executing cost savings and ERP benefits, while the main risk is that ongoing cost inflation and value focused consumers keep squeezing margins and volume.

Among recent announcements, the ongoing share repurchase program stands out alongside the reaffirmed FY2026 guidance at the lower end of prior ranges. Together, they frame the current results in a context of cautious confidence: management is still returning cash to shareholders while acknowledging a tougher top line backdrop, which matters if you are focused on how quickly cost initiatives and innovation can offset competitive discounting and slower demand.

Yet beneath these steady headlines, investors should be aware of how persistent cost inflation and tariff pressures could still...

Clorox's narrative projects $7.0 billion revenue and $881.8 million earnings by 2028. This assumes a 0.4% yearly revenue decline and about an $71.8 million earnings increase from $810.0 million today.

Uncover how Clorox's forecasts yield a $119.76 fair value, a 23% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts expected earnings near US$939.7 million by 2028, but with Q3 softness and ongoing cost inflation, you should recognize how differently reasonable people can view Clorox’s ERP driven margin potential and decide which narrative fits your own expectations.

Explore 7 other fair value estimates on Clorox - why the stock might be worth 7% less than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Clorox research is our analysis highlighting 5 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Clorox research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Clorox's overall financial health at a glance.

Looking For Alternative Opportunities?

Our top stock finds are flying under the radar-for now. Get in early:

• Capitalize on the AI infrastructure supercycle with our selection of the 38 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Find 54 companies with promising cash flow potential yet trading below their fair value.
• Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.